PACE-NODES: A phase III randomised trial of 5 fraction prostate stereotactic body radiotherapy (SBRT) versus 5 fraction prostate and pelvic nodal SBRT

Clinical and Translational Radiation Oncology 2026 Open access

Read full text
Authors: Angela Pathmanathan, Suneil Jain, John Staffurth, Stephanie Brown, Stephanie Burnett, Fay Helen Cafferty, Ananya Choudhury, Monisha Dewan, Peter Hoskin, Ken McBride, Conor K McGarry, Elizabeth A. Miles
+9 more Julia R. Murray, Vedang Murthy, Olivia Frances Naismith, Yee Pei Song, Isabel Syndikus, Alison Tree, Tim H. Ward, Emma Hall, Nicholas van As
DOI: 10.1016/j.ctro.2026.101126
Cited by: 1
References: 27

Abstract

PACE-NODES is a phase III randomised controlled trial for patients with high risk localised prostate cancer, planned for radical radiotherapy with at least 12 months of androgen deprivation therapy, and suitable for stereotactic body radiotherapy (SBRT). Patients are randomised to receive either prostate SBRT (control) or prostate and pelvic nodal SBRT. In both arms, treatment is given in 5 fractions delivered on alternate days over 2 weeks. The aim of the trial is to determine whether prostate and pelvic nodal SBRT can improve outcomes for this patient group compared to prostate SBRT. Clinical trial registration: PACE NODES is registered on ClinicalTrials.gov (NCT05613023).

Fields of Study & Subjects

Prostate Cancer Diagnosis and Treatment Advanced Radiotherapy Techniques Prostate Cancer Treatment and Research

Publication details

Journal / source
Clinical and Translational Radiation Oncology
Publisher
Elsevier BV
Volume
58
Pages
101126–101126
Publication date
12 February 2026
Language
EN